SHP (small heterodimer partner; NR0B2) is an atypical orphan NR (nuclear receptor) that functions as a transcriptional corepressor by interacting with a diverse set of NRs and transcriptional factors. HNF-6 (hepatocyte nuclear factor-6) is a key regulatory factor in pancreatic development, endocrine differentiation and the formation of the biliary tract, as well as glucose metabolism. In this study, we have investigated the function of SHP as a putative repressor of HNF-6. Using transient transfection assays, we have shown that SHP represses the transcriptional activity of HNF-6. Confocal microscopy revealed that both SHP and HNF-6 co-localize in the nuclei of cells. SHP physically interacted with HNF-6 in protein-protein association assays in vitro. EMSAs (electrophoretic mobility-shift assays) and ChIP (chromatin immunoprecipitation) assays demonstrated that SHP inhibits the DNA-binding activity of HNF-6 to an HNF-6-response element consensus sequence, and the HNF-6 target region of the endogenous G6Pase (glucose 6-phosphatase) promoter respectively. Northern blot analysis of HNF-6 target genes in cells infected with adenoviral vectors for SHP and SHP siRNAs (small inhibitory RNAs) indicated that SHP represses the expression of endogenous G6Pase and PEPCK (phosphoenolpyruvate carboxykinase). Our results suggest that HNF-6 is a novel target of SHP in the regulation of gluconeogenesis.
INTRODUCTION
The atypical orphan NR (nuclear receptor) SHP (small heterodimer partner) appears to be a versatile protein that functions in many cellular events. It has an atypical structure, consisting of a putative LBD (ligand-binding domain) and lacking a classical DBD (DNA-binding domain) [1] . SHP is expressed predominantly in the liver, and is also detected in the heart, lung, pancreas, spleen, kidney, smooth muscle, testis and ovary, where it has been shown to have a variety of functions, most notably that of a co-regulator in general, and a co-repressor of transcription factors and NRs [1] [2] [3] [4] . Previously, SHP has been implicated in glucose regulation, thereby raising the possibility that SHP plays a more general role in metabolic regulation [5] [6] [7] [8] . Structurally, SHP harbours two functional LXXLL-like motifs (also called NR-boxes), which are typical of NR-binding proteins, including co-activators [9] . To date, SHP has been shown to interact with nearly half of all mammalian NRs. SHP has been shown to interact with and down-regulate the transcriptional activity of CAR (constitutive androstane receptor) [1] , RAR (retinoic acid receptor) [1] , ER (oestrogen receptor) α and β [2] , ERR (ERrelated receptor) [3] , GR (glucocorticoid receptor) [5] , AR (androgen receptor) [10] , HNF (hepatocyte nuclear factor)-4 [6, 11] , RXR (retinoid X receptor) [11] , LXR (liver X receptor) α and β [12] , PXR (pregnane X receptor) [13] , LRH-1 (liver receptor homologue 1) [14] , Nur77 [15] and PPAR (peroxisome proliferator-activated receptor) α [16] and γ [17] . These findings suggest that SHP is involved in a complex regulatory network comprised of a variety of NRs. In addition to members of the NR superfamily, SHP has also been shown to interact with other non-NR transcription factors, suggesting that SHP has additional functions in NR-independent transcriptional pathways. SHP has been shown to interact with the NF-κB (nuclear factor-κB) component p65 [17] , Id (inhibitor of differentiation) proteins [18] , forkhead transcription factor HNF-3/Foxa [7] and BETA2/ NeuroD [19] . SHP also interacts directly with Foxo1 (also called FKHR) [6] , JunD [20] , PMA-induced c-Jun [21] and Smad [22] . The fact that SHP interacts with such a diverse array of NRs and transcriptional factors indicates that SHP is involved in the regulation of a variety of cellular events [23, 24] .
Three putative mechanisms of transcriptional repression of NRs and transcription factors by SHP have been proposed: competition for co-activators, blocking of DNA binding and the recruitment of co-repressors. SHP contains two LXXLL-like motifs which mediate interactions with the AF (activation function)-2 domains of NRs. Thus SHP can compete with co-activators that specifically interact with NR AF-2 domains, resulting in the repression of NR-mediated transcriptional activity. It has been
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shown, for example, that SHP inhibits ERα and ERβ activity through the inhibition of their AF-2 domains by competing directly for binding to TIF2 (transcription intermediary factor 2) [2] . SHP has also been shown to interact directly with the surfaces of NRs and transcription factors and block the DNA binding of transcriptional regulators to target genes. This mechanism of inhibition appears to be involved in the repression of HNF-3β-mediated transactivation of its target genes [7] . The third mechanism of repression by SHP involves co-repressor recruitment. SHP contains several amino acid residues that reside between helix 6 (H6) and helix 7 (H7) of the LBD, termed the repression domain, which participate in the repression of transactivation of target genes by recruiting the EID-1 (E1A-like inhibitor of differentiation 1) co-repressor [25, 26] . The repression domain of SHP also interacts with the Swi/Snf co-repressor complex [27] and HDAC (histone deacetylase)-1 [28, 29] . Thus it appears that SHP negatively regulates NRs and transcription factors though several different mechanisms. HNF-6 (also called OC-1) is a liver-enriched transcription factor that was originally identified as a transcriptional activator of liver 6-phosphofructo-2-kinase, an enzyme involved in the regulation of glycolysis and gluconeogenesis [30] . The structure of HNF-6 comprises a single 'cut' domain and a divergent 'homeo'-domain. HNF-6 is also expressed in the pancreas, brain, spleen and testis [30] [31] [32] . Two additional HNF-6 family members have been identified, termed OC-2 [33] and OC-3 [34] , and appear to have similar properties to HNF-6. It has been reported that HNF-6 plays an important role in the specification or development of the pancreas, endocrine differentiation, bile duct formation and the development of islet β cells [31, 32, [35] [36] [37] . Mice that are genetically deficient in HNF-6 (HNF-6 −/− mice) are diabetic and have a hypoplastic pancreas [35] . At the molecular level, HNF-6 has been shown to bind to and activate the promoters of several genes involved in the control of glucose metabolism. Several transcriptional targets of HNF-6 have been identified, including 6-phosphofructo-2-kinase [30] , Ngn-3 (neurogenin 3) [35] , HNF-3β [31, 32, 38] , TTR (transthyretin) [31, 38] , protein C [39] , CYP2C12 [40] , glucokinase [41] , CYP7A1 [42] , GLUT2 (glucose transporter protein 2) [43] , G6Pase (glucose 6-phosphatase) [44, 45] and PEPCK (phosphoenolpyruvate carboxykinase) [38] . These results suggest that HNF-6 is involved in the liver-specific expression of several genes.
In this study, we have investigated the effect of SHP on HNF-6. We have demonstrated that SHP physically interacts with HNF-6 and represses HNF-6 transcriptional activity by blocking the ability of HNF-6 to bind to DNA sequences in target promoters. SHP also repressed the expression of HNF-6 target genes that are involved in glucose metabolism. Our results identify HNF-6 as a novel target of SHP in hepatocytes.
MATERIALS AND METHODS

Plasmids and DNA construction
The reporter plasmids OATP (organic anion transporting polypeptide)-C128/Luc, 6 × FoxA (forkhead box A2, previously called HNF-3β)-Luc, 8 × HNF-4α-Luc, 6 × HNF-6-Luc and G6Pase-Luc were previously described in [7] . PEPCK-Luc was provided by Dr Richard W. Hanson (Case Western Reserve University School of Medicine, Cleveland, OH, U.S.A.). PEPCK (mt)-Luc was generated by double point mutation of the HNF-6 binding site of the PEPCK promoter (− 256/TAGTCAATCA/ − 247 was changed to TAGTCTTTCA, target nucleotides underlined). The HA (haemaglutinin)-tagged constructs pcDNA3/HA-SHP, pcDNA3/HA-HNF-1α and pcDNA3/HA-HNF-3β were previously described in [7] . pcDNA3/HA-HNF-4α was provided by Dr Yoon-Kwang Lee (Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, U.S.A.) [11] . The cDNAs for the construction of the HNF-6, OC-2, and OC-3 expression vectors were a gift from Dr Frédéric P. Lemaigre (Hormone and Metabolic Research Unit, Université Catholique de Louvain, Belgium). HA and GST (glutathione transferase) fusion protein expression vectors were constructed using pcDNA3/HA and pGEX4T1, respectively. pRC-RSV-PKA (protein kinase A catalytic subunit) was provided by Dr Richard A. Maurer (Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, OR 97201, U.S.A.). GST-SHP and the SHP deletion constructs were previously described in [7] . The HNF-6 deletion constructs m1-m5 were generated using PCR to amplify the appropriate sequences, followed by insertion of the amplified fragments into the EcoRI/XhoI sites of pGEX4T-1. All plasmids were confirmed by automatic sequence analysis.
Cell culture and transient transfection assay
HepG2 human hepatocellular liver carcinoma cells were maintained in DMEM (Dulbecco's modified Eagle's medium; Hyclone, 1725 South Hyclone Road Logan, UH, U.S.A.) supplemented with 10 % FBS (fetal bovine serum; Hyclone) and antibiotics (Hyclone) in a humidified atmosphere containing 5 % CO 2 at 37
• C. The day before transfection, cells were seeded into 24-well plates at a density of 2-8 × 10 4 cells/well. Transient transfections were carried out using Lipofectamine 2000 TM (Invitrogen) according to the manufacturer's instructions. The cells were cotransfected with a reporter plasmid and the indicated amount of expression vector. The total amount of DNA was adjusted to 1 μg/well with the addition of pcDNA3. A CMV (cytomegalovirus) β-galactosidase plasmid (pCMV-β-galactosidase, 0.1 μg) was co-transfected as an internal control. The cells were harvested 24 h after transfection and luciferase activity was measured. Luciferase activity was normalized to β-galactosidase activity. The results shown are representative of at least three to five independent experiments. All data was analysed using the Student's t test, and statistically significant data points are indicated with an asterisk in the Figures.
RT-PCR (reverse transcription-PCR) analysis
HepG2 cells were transfected with 0.5-1.5 μg of pcDNA3/HA-HNF-6 together with 0.5-1.5 μg of pcDNA3/FLAG-SHP or pcDNA3 (empty vector). The cells were harvested 24 h after transfection and total RNA was isolated using the TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RT-PCR was performed using 0.5 μg of total RNA and the following primers: for HNF-6, forward 5 -ATGAATAACCTCTATACC-CC-3 and reverse 5 -CCTGAATTACTTCCATTGCT-3 ; for SHP, forward 5 -CTTCCTCAGGAACCT-3 and reverse 5 -CCCA-GTGAGCCTCCT; for β-actin, forward 5 -GCTGAGAGGGAA-ATCGTGCGT-3 and reverse 5 -AATGATCTTGATCTTCAT-GGT-3 . The primers were designed based on the consensus sequences of the ORFs (open reading frames) of each gene in human, rat and mouse. The expected sizes of the amplified products for HNF-6, SHP, and β-actin were 389, 380 and 380 bp respectively.
Western blot analysis
HepG2 cells were transfected with 0.5-1 μg of pcDNA3/HA-HNF-6 together with 0.5-1.5 μg of pcDNA3/FLAG-SHP or empty vector. Cell lysates were prepared 24 h after transfection using RIPA buffer [50 mM Tris/HCl, pH 8.0, 5 mM EDTA, 150 mM NaCl, 1 % NP 40 (Nonidet P40), 0.1 % SDS and 1 mM PMSF] (Elpis-Biotech, Taejeon, South Korea). Proteins from whole cell lysates were separated by SDS/10 % PAGE and then transferred to nitrocellulose membranes (ProTran; Whatman Gmbh, Germany). The membranes were probed with anti-HNF-6 antibodies (sc-13050; Santa Cruz Biotechnology, California, U.S.A.) and rat anti-SHP polyclonal antibodies that were raised against bacterially-expressed 6 × His-tagged SHP. Immunoreactive proteins were visualized using an ECL ® (enhanced chemiluminescence) kit (Amersham Biosciences) according to the manufacturer's instructions. To determine the relative amounts of HA-HNF-6 and FLAG-SHP in each experiment, membranes were reprobed with a monoclonal anti-HA antibody (12CA5; Roche Molecular Biochemicals, Indianapolis, IN, U.S.A.) and an anti-FLAG antibody (Stratagene, La Jolla, CA, U.S.A.) respectively.
Confocal microscopy
NIH 3T3 mouse embryonic fibroblast cells were grown on uncoated glass coverslips and transfected with pEGFP-SHP and pcDNA3/HA-HNF-6 using Lipofectamine 2000 TM reagent. The cells were fixed 24 h after transfection for 40 min in 3.7 % formaldehyde, mounted on glass slides and observed using a laserscanning confocal microscope (Olympus, Lake Success, NY, U.S.A.). For the detection of HNF-6, the cells were permeabilized in 2 ml of PBS containing 0.1 % Triton X-100 and 0.1 M glycine at room temperature (25
• C), incubated for 15 min, washed three times with 1 × PBS and then blocked for 10 min with 3 % (w/v) BSA in PBS at room temperature. The cells were incubated with primary anti-HA antibody for 1 h at 37
• C, washed three times in 1 × PBS and then incubated for 1 h with Rhodamine-conjugated anti-rabbit secondary antibody (Jackson Immuno Research Laboratories, West Grove, PA, U.S.A.) at 37
• C.
In vivo GST pull-down assay
HEK-293T cells [HEK (human embryonic kidney)-293 cell expressing the large T-antigen of SV40 (simian virus 40)], in DMEM supplemented with 10 % FBS, were seeded into six-well flat-bottomed microplates at a concentration of 2 × 10 5 cells per well 1 day before transfection, as previously described [7] . In brief, HEK-293T cells were transfected with 1 μg of each of the indicated plasmids by calcium phosphate precipitation. The cells were collected and solubilized 24 h after transfection, and the cleared lysates were incubated with 15 μl of glutathioneSepharose beads (GE Healthcare Bio-Sciences) with rotation for 2 h at 4
• C. Bound proteins were eluted by boiling the beads in SDS sample buffer, then separated by SDS/PAGE and transferred to PVDF membranes (Millipore). The membranes were probed with anti-HA antibodies and immunoreactive proteins were detected using an ECL ® kit.
GST pull-down assay
GST-fusion proteins or GST alone were bacterially expressed and isolated using glutathione-Sepharose beads, as described previously in [19] . Recombinant SHP, HNF-6 and their corresponding deletion mutants were radiolabelled with [
35 S]methionine using a coupled TNT (transcription and translation) system [TNT-coupled reticulocyte lysate system; Promega] according to the manufacturer's instructions. GST fusion proteins coupled to glutathione-Sepharose beads were incubated with in vitro-translated proteins in binding buffer A containing 25 mM Hepes (pH 7.6), 150 mM NaCl, 0.2 mM EDTA, 1 mM dithiothreitol, 1 mM PMSF, and 20 % glycerol for 4 h at 4
• C. The beads were then washed three times with binding buffer A containing 200 mM NaCl and bound proteins were separated by SDS/10 % PAGE. The gels were visualized directly using a phosphorimager (BAS-1500; Fuji, Tokyo, Japan). The deletion mutants used in the analysis were as follows: GST-SHP (m1), aa 1-156; GST-SHP (m2), aa 157-257; HNF-6 (m1), aa 1-288; HNF-6 (m2), aa 289-384; HNF-6 (m3), aa 362-465; HNF-6 (m4), aa 1-384; HNF-6 (m5), aa 289-465.
EMSA (electrophoretic mobility-shift assay)
EMSA was performed as previously described in [7] . Briefly, double-stranded oligonucleotides containing the HNF-6 consensus binding site were generated and labelled with [α-32 P]dCTP using the Klenow fragment of DNA polymerase I. The oligonucleotide sequences were as follows: sense, 5 -GGGCCCGATA-TTGATTT-3 and antisense, 5 -GGGAAATCAATATCGGG-3 . Purified recombinant proteins (HNF-6, SHP and Dax-1) were generated by in vitro translation using a TNT-coupled reticulocyte lysate system. Unprogrammed free lysate was used as a control. The binding reactions were carried out in binding buffer B containing 20 % glycerol, 100 mM Tris/HCl (pH 8.0), 100 mM KCl, 25 mM MgCl 2 , 500 μg/ml of BSA, 1 mM dithiothreitol and 1 μg of poly(dI-dC). HNF-6 (1-2 μl) and the indicated amounts of SHP or Dax-1 were mixed with 10 000 c.p.m. of labelled HNF-6 consensus oligonucleotide in a 20 μl reaction. Unlabelled oligonucleotide containing the HNF-6 binding site or AR binding site were used as the positive (+) and negative (−) competitor oligonucleotides respectively. Reactions were allowed to proceed for 15 min, and then DNA-protein complexes were separated by 4 % PAGE in 0.5 × TBE (90 mM Tris, 90 mM boric acid and 2 mM EDTA). The gels were dried and then analysed by autoradiography.
ChIP (chromatin immunoprecipitation) assay
ChIP assays were performed as described previously in [7] . Briefly, HepG2 cells were seeded into 60 mm culture dishes then co-transfected with 3 μg of pcDNA3/HA-HNF-6 and 3-6 μg of pcDNA3/FLAG-SHP or empty vector as a control. The cells were fixed 24 h after transfection with 1 % formaldehyde, washed with ice-cold PBS, and harvested. The cells were sonicated and soluble chromatin was subjected to immunoprecipitation using monoclonal anti-HA antibody-coupled agarose beads (A2095; Sigma-Aldrich, U.S.A.) or anti-FLAG antibodies followed by Protein A agarose/salmon sperm DNA (Upstate, Temecula, CA, U.S.A.). DNA was recovered by phenol/chloroform extraction and amplified by PCR for 30 cycles using primer sets that encompassed the proximal (− 307 to + 13 bp, relative to the transcriptional start site at + 1 bp) or distal (− 1299 to − 1010 bp) region of the human G6Pase promoter. The primer sequences were as follows: proximal, forward 5 -GATGTAGACTCTGTCCTG-3 and reverse 5 -GATTGCTCTGCTATGAGT-3 ; distal, forward 5 -CACTTGGCCAGGCATGGTGG-3 and reverse 5 -TTTGAA-ACAGGGTCTCACTCT-3 . HNF-6 binding sites are located in the proximal region of the G6Pase promoter.
siRNA (small inhibitory RNA) expression
The siRNAs for SHP (SHP siRNA 1 and 2) were previously described in [7] . HepG2 cells were transfected with siRNAs using the Oligofectamine reagent (Invitrogen). The cells were harvested 24 h after transfection, and total RNA was isolated using the TRIzol reagent according to the manufacturer's instructions. HepG2 human hepatoma cells were co-transfected with 200 ng of the indicated luciferase reporter construct and 100 ng of pcDNA3/HA harbouring HNF-1α (A), HNF-3β (B), HNF-4α (C) or HNF-6 (D), together with the indicated amount of pcDNA3/FLAG-hSHP. Empty vector (pcDNA3) was used to adjust the total amount of DNA in each transfection, and 100 ng of pCMV-β-galactosidase was used as an internal control. Cells were harvested 24 h after transfection, and luciferase activity was measured and normalized to β-galactosidase activity.
* P < 0.01. The levels of mRNA and protein expression of each construct were determined using RT-PCR analysis of total RNA with the indicated primers (E), and Western blot analysis of protein extracts with the indicated antibodies (F) respectively. The apparent molecular weight of HNF-6 is 52 kDa and SHP is 28 kDa.
The siRNA sequences were as follows: SHP siRNA 1, sense 5 -CCTGCCATCCTTCTGGCAGdTdT-3 ; SHP siRNA 2, sense 5 -GTCCATTCCGACCAGCCTGdTdT-3 .
Recombinant adenovirus preparation and virus infection
Ad-SHP, the adenoviral vector encoding full-length human SHP, was described previously in [7] . The adenoviral vector for the SHP siRNA, Ad-siSHP, was constructed as follows. The mouse cDNA sequence (239-GACAGTAGCCTTCCTCAGGAA-259) corresponding to the SHP siRNA sequence was incorporated into the shuttle vector pADTrack-CMV. The shuttle vector was transfected into BJ5138 Escherichia coli cells by electroporation, and the recombinant adenoviral vector was generated using the AdEasy adenoviral vector system. Recombinant viruses were then amplified in HEK-293 cells and isolated by cesium chloride density gradient centrifugation (Sigma). Virus was collected and desalted, and the titre was measured using Adeno-XTM Rapid titer (BD Biosciences) according to the manufacturer's instructions. Cells were infected at a MOI (multiplicity of infection) of 50 using Ad-SHP or Ad-siSHP in DMEM for 3 h. Following viral infection, the culture medium was replaced with fresh DMEM containing 0.5 % FBS.
Northern blot analysis
Total RNA was isolated using the TRIzol reagent according to the manufacturer's instructions. Total RNA (20 μg) was separated on a 0.8 % denaturing agarose gel by electrophoresis, then transferred to a nitrocellulose membrane (Zeta-Probe; BioRad Laboratories). The membrane was exposed to UV light to crosslink the RNA, and then incubated with a radiolabelled probe for detecting the expression of SHP, G6Pase, PEPCK or GAPDH (glyceraldehyde-3-phosphate dehydrogenase). Probes were generated using a random primer DNA-labelling system and [α-
32 P]dCTP. The level of expression of all transcripts was normalized to the level of GAPDH expression.
RESULTS
SHP represses the transcriptional activity of liver-enriched nuclear factor HNF-6
Previous reports have shown that SHP represses several HNFs, including HNF-3α, -3β and -3γ [7] and HNF-4 [6] , and regulates gluconeogenesis in the liver. To determine whether SHP is involved in the regulation of HNF-6 activity, we initially compared the effect of SHP overexpression on the transcriptional activity of HNF-6 to that of several other HNF family members in HepG2 human hepatoma cells. Consistent with a previous report [7] , transient expression of SHP did not significantly repress the transcriptional activity of HNF-1α towards its cognate reporter gene ( Figure 1A ), whereas it repressed the transcriptional activity of HNF-3α and -3γ (results not shown), HNF-3β, HNF-4α, and HNF-6 in a dose-dependent manner (Figures 1B-1D) . Moreover, the transfection of a relatively low amount of SHP expression vector resulted in a significant repression of HNF-6-dependent transcriptional activity using a 6 × HNF-6 TATA-luciferase reporter gene ( Figure 1D ). SHP overexpression had no detectable effect on the levels of HNF-6 mRNA or protein ( Figures 1E and 1F) , although the levels of expression of endogenous SHP and HNF-6 were below the limit of detection by Western blot ( Figure 1F ). These results indicated that SHP represses HNF-6 transcriptional activity, similar to other HNFs.
It has been reported that the HNF-6 family members OC-2 and OC-3 function similarly to HNF-6 [33, 34] . To determine whether SHP regulates other HNF-6 family members, we assessed the effect of SHP on the transcriptional activity of OC-2 and OC-3. OC-2 and OC-3 significantly increased the expression of the 6 × HNF-6 TATA-luciferase reporter gene in a dose-dependent manner (results not shown), and this effect was repressed by SHP (Figures 2A and 2B ). These results indicated that SHP also exerts a repressive effect on HNF-6 family members. SHP and HNF-6 are expressed primarily in the liver, where they regulate a variety of transcriptional factors [1, 23, 30, 38] . To determine whether HNF-6 is regulated by endogenous SHP, we examined HNF-6 transcriptional activity in cells in which SHP expression was blocked by siRNA ( Figure 2D ). As seen in Figure 2(C) , the transcriptional activity of HNF-6 was repressed by endogenous GST pull-down assay. HEK-293T cells were co-transfected with expression vectors for HA-HNF-6 and GST-SHP (pEBG-SHP) or GST alone (pEBG) as a control. Cells were lysed 24 h after transfection, and protein complexes were isolated using glutathione-Sepharose. Bound proteins were subject to Western blot using anti-HA antibodies (top). The blot was then stripped and re-probed with anti-GST antibodies (middle) to determine the expression levels of GST-SHP or GST alone (GST). The expression of HA-HNF-6 was analysed by Western blot using whole cell lysate (bottom). SHP. These results identify HNF-6 as a novel target of SHP among the liver-enriched transcriptional factors.
SHP and HNF-6 co-localize in the nucleus and physically interact with each other
To determine the subcellular localization pattern of SHP and HNF6, we performed immunofluorescence confocal microscopy. Consistent with previous reports, the majority of SHP localized to the nuclei of cells ( Figure 3A ). HNF-6 also localized to the same region, indicating that SHP and HNF-6 co-localize to the same cellular compartment.
SHP mediates its repressive effects by interacting directly with many transcription factors and NRs [23, 24] . To determine whether SHP physically interacts with HNF-6 in cells, we carried out a GST pull-down assay. HEK-293T cells were co-transfected with expression vectors for HA-HNF-6 and GST-SHP, or GST alone, and protein complexes were isolated using glutathioneSepharose. As shown in Figure 3 (B), HNF-6 specifically interacted with GST-SHP but not GST alone (top). The expression levels of each protein were verified by Western blot using antibodies specific for GST and HA ( Figure 3B , middle and bottom respectively). These results indicated that SHP and HNF-6 co-localize to the nuclei of cells, and SHP physically interacts with HNF-6 in cells.
SHP directly interacts with the N-terminus but not the cut domain or the homeodomain of HNF-6
It has been reported that both the 'cut'-and 'homeo'-domains of HNF-6 are important for DNA binding and transcriptional activation of target genes [30] . It has also been shown that SHP inhibits the DNA-binding activity and represses the transcriptional activity of HNF-3 by interacting directly with the HNF-3 DBD [7] . To identify the domains that are involved in the interaction between SHP and HNF-6, we performed a GST association assay using in vitro translated wild-type and mutant forms of SHP and HNF-6. Figures 4(A) and 4(B) show schematic representations of the structures of wild-type and deletion mutants of rat HNF-6 ( Figure 4A ) and human SHP ( Figure 4B ). Recombinant GST fusion proteins were expressed in bacteria and purified, and 35 S]-labelled HNF-6 interacted with full-length and deletion mutants of GST-SHP, although the binding of HNF-6 to SHP (m2), which harbours the SHP repression domain, was only slightly stronger than SHP (m1), which harbours the interaction domain ( Figure 4D ). The cut-and homeo-domains of HNF-6 exhibited minimal binding to SHP. To confirm this result, in vitro translated [ 35 S]-labelled HNF-6 and HNF-6 deletion mutants were incubated individually with GST-SHP. As shown in Figure 4 (E), SHP interacted strongly with the N-terminal region of HNF-6, but not the cut-and homeo-domains. We observed relatively weak binding between SHP and HNF-6 (m5), which contained both the cut-and homeo-domains. These results indicated that SHP interacts directly with the N-terminal region of HNF-6, rather than the HNF-6 cut-or homeo-domain.
SHP inhibits the DNA binding of HNF6 in vitro and in vivo
SHP was unable to bind to the cut-and homeo-domains of HNF-6, which are crucial for DNA binding and the transcriptional activation of target genes (Figure 4) . On the basis of these results, we initially hypothesized that SHP represses the transcriptional activity of HNF-6 by competing for binding to cofactors. Previously, it was reported that the acetylation of HNF-6 by CBP [CREB (cAMP-response-element-binding protein)-binding protein]/p300 enhanced both the protein stability and transactivity of HNF-6 [46] . When we examined the ability of SHP to compete with HNF-6 for binding to CBP/p300, PGC-1 (PPARγ co-activator 1), SRC1 (steroid receptor co-activator 1) and GRIP1 (glutamate receptor-interacting protein 1), we found no significant co-activator activity or clear evidence of competition between SHP and these putative co-activators (Supplementary Figure 1, at http://www.BiochemJ.org/bj/413/bj4130559add.htm). Since it has been shown that SHP represses HNF-3 transactivity by blocking DNA binding [7] , we next performed a gel shift assay to determine whether SHP also inhibited the DNA binding of HNF-6 to target gene promoters. As shown in Figure 5 (A), in vitrotranslated HNF-6 bound to the core consensus HNF-6-binding sequence of the HNF-3β promoter ( Figure 5, lanes 3 and 4) , and binding was decreased significantly by the addition of in vitrotranslated SHP in a dose-dependent manner ( Figure 5 , lanes 9, 10 and 11). Unprogrammed cell lysate ( Figure 5, lane 2) and the control protein Dax-1 ( Figure 5, lane 12) , which is a close relative of SHP, did not inhibit the interaction of HNF-6 with DNA. These in vitro results indicated that SHP inhibits the DNAbinding activity of HNF-6.
We also performed a ChIP assay in transiently transfected HepG2 cells to confirm the affect of SHP on the DNA-binding activity of HNF-6. As shown in Figure 5 (B), HA-HNF-6 bound to the proximal (− 307/+ 13 bp) region of the hG6Pase promoter, which harbours an HNF-6 binding site, and co-expression of FLAG-SHP strongly repressed the binding of HNF-6 to its promoter ( Figure 5B, upper panel, top) . HNF-6 did not bind to the distal (− 1299/− 1010 bp) region of the promoter, which does not contain an HNF-6 binding site ( Figure 5B, upper panel, bottom) . In the control experiment using anti-FLAG antibodies, amplified PCR products were undetectable using either primer set, which indicated that SHP does not interact with the DNA directly, but inhibits the binding of HNF-6 to its target site ( Figure 5B , lower panel). These results indicated that SHP inhibits the DNA binding of HNF-6 to target gene promoters in vivo, and that the mechanism of repression of HNF-6 transactivity by SHP involves blocking of DNA binding, rather than cofactor competition.
SHP represses HNF-6-mediated transcriptional activation of the gluconeogenic genes G6Pase and PEPCK
HNF-6 binds to the promoters of key gluconeogenic genes, including G6Pase [44, 45] and PEPCK [38] . We were interested promoter. Unprogrammed TNT-coupled reticulocyte lysate was used as a negative control. The volume of protein or oligonucleotide is expressed in μl. DNA-protein complexes were analysed by 4 % PAGE, followed by autoradiography. (+) and (−) Comp., positive and negative competitor. (B) ChIP assay. HepG2 cells were co-transfected with 3 μg of pcDNA3/HA-HNF-6 and 3-6 μg of pcDNA3/FLAG, or pcDNA3/FLAG-SHP. Whole cell lysates were prepared 24 h after transfection and subjected to immunoprecipitation using monoclonal antibodies directed against HA or FLAG, and the isolated DNA sequences were analysed by PCR. Primers were designed to amplify the proximal (− 307/+ 13 bp) region of the hG6Pase promoter, which harbours an HNF-6 binding site (upper and lower panel, top). The distal (− 1299/− 1010 bp) region of the hG6Pase promoter, which does not contain an HNF-6 binding site, was used as a negative control (-CTL, upper and lower panel, bottom). The input, whole cell lysate (10 %) was used as the input control. 'M' represents DNA size markers.
in whether SHP repressed the HNF-6-mediated transcriptional activation of gluconeogenic genes, similar to its effect on HNF-3β [7] and HNF-4α [6] . As shown in Figures 6(A) and 6(B) , HNF-6 increased the activity of the G6Pase and PEPCK-luciferase reporter genes in a dose-dependent manner, although the response of G6Pase-Luc to HNF-6 was lower than PEPCK-Luc, and SHP significantly repressed the transactivation of both reporter genes ( Figures 6C and 6D) . To verify the functional portion of HNF-6 on the gluconeogenic genes and the effects of SHP, we modified the PEPCK-luc reporter gene, inserting a double point mutation into the HNF-6 binding site (TAGTCAATCA to TAGTCTTTCA). As shown in Figure 6 (E), the promoter activity of wild-type PEPCK was significantly increased by HNF-6 in a dose-dependent manner, and this increase in activity was repressed by SHP. In contrast, the mutated promoter was unresponsive to low levels of HNF-6, and was slightly increased by high doses (400 ng) of HNF-6, suggesting that there might be other transcription factors , SHP represses the HNF-6-mediated transcriptional activity of G6Pase and PEPCK. Cells were co-transfected with reporter constructs, as described for (A) and (B), and the indicated amounts of pcDNA3/HA-HNF-6 and pcDNA3/FLAG-hSHP. (E) and (F), SHP represses the HNF-6-specific transcriptional activity of PEPCK. Cells were co-transfected with wild-type (wt) PEPCK-Luc, or PEPCK (mt)-Luc, in which the HNF-6 binding site was mutated, and the indicated amounts of pcDNA3/HA-HNF-6, pcDNA3/FLAG-hSHP and pRC-RSV-PKA. pcDNA3 was used to adjust the total amount of DNA used in each transfection, and 100 ng of pCMV-β-galactosidase were used as an internal control. The cells were harvested 24 h after transfection, and luciferase activity was measured. Luciferase activity was normalized to β-galactosidase activity.
* P < 0.02.
that are involved in the HNF-6-dependent activation of PEPCK gene expression. It has been reported that HNF-6 is phosphorylated by PKA and that PKA stimulates the transcriptional activity of G6Pase [44] . To determine the effect of PKA on HNF-6-dependent PEPCK transactivation, we again performed a transient transfection assay using expression vectors for HNF-6 and PKA.
As shown in Figure 6 (F), the promoter activity of wild-type PEPCK was significantly increased by PKA, and this increase in activity was repressed by SHP. Co-expression of HNF-6 increased the PKA-induced activation of the PEPCK promoter, whereas the mutated PEPCK promoter was not responsive to PKA or HNF-6. Taken together, these results indicated that SHP represses the HNF-6-mediated transcriptional activation of G6Pase and PEPCK, and that HNF-6 is a novel target of SHP involved in the regulation of gluconeogenesis.
SHP represses the expression of the gluconeogenic genes G6Pase and PEPCK
To determine whether SHP has any effect on the expression of endogenous G6Pase and PEPCK, we examined the effect of overexpression or inhibition of expression of SHP in hepatocytes. The overexpression of SHP by infection with Ad-SHP repressed the expression of endogenous G6Pase, while the inhibition of SHP expression with SHP siRNA induced the expression of G6Pase ( Figure 7A ). We also investigated the effect of SHP on forskolininduced expression of G6Pase and PEPCK. H4IIE rat hepatoma cells were infected with Ad-SHP or Ad-siSHP, and then treated with forskolin to induce the expression of glucogenic genes. As shown in Figure 7 (B), the overexpression of SHP repressed both endogenous and forskolin-induced G6Pase and PEPCK gene expression, and this repression was relieved by Ad-siSHP. These results indicate that SHP represses the expression of the HNF-6 target genes G6Pase and PEPCK, which are involved in glucose metabolism.
DISCUSSION
SHP is an orphan NR that interacts with a variety of transcription factors to negatively regulate target genes [23] . Recently, SHP has been the subject of a great deal of attention due to its crucial function in glucose metabolism [5] [6] [7] [8] . SHP represses gluconeogenic gene expression by inhibiting the function of HNFs [6, 7] . In the present study, we examined the effect of SHP on HNF-6, a liver-enriched factor, and found that SHP has a repressive effect on the HNF-6-mediated transactivation of target gene expression. Our results identify HNF-6 as a novel target of SHP in hepatocytes. Previously, it was reported that SHP competes with the transcriptional co-activator PGC-1 to inhibit the transactivation of the PEPCK promoter by GR and HNF-4 [5] . In addition, bile acid induces the expression of SHP, which then represses the expression of gluconeogenic genes through the dissociation of Foxo1 or HNF-4 with CBP [6] . These results have strongly implicated cofactor competition as a mechanism of repression of gene expression by SHP. In the present study, we demonstrated that SHP interacts directly with HNF-6 and inhibits the DNA binding of HNF-6 to its target promoter. Thus the mechanism of inhibition by SHP may vary, depending on the targeted transcription factor. We also demonstrated that SHP interacts with the N-terminal portion of HNF-6, rather than the cut-or homeo-domain, which are crucial for DNA binding (Figure 4) . Thus it appears that SHP may also repress the transcriptional activity of HNF-6 through interaction with the Nterminal region of HNF-6. Supporting this idea, it has been shown that HNF-6 stimulates transcription through an N-terminal STP (serine/threonine/proline) box domain [46] . With regards to the inhibition of HNF-6 DNA binding activity by SHP, it is possible that the interaction of SHP with HNF-6 induces a conformational change in HNF-6 or obscures the DNA-binding region of HNF-6, thus preventing access to target DNA sequences and inhibiting DNA binding. We cannot completely rule out the possibility that SHP competes with certain cofactors of HNF-6 as it has been shown that HNF-6 can function via different, sequence-specific, mechanisms which are a combination of distinct modes of DNA binding and interaction with different co-activators [45] [46] [47] . We demonstrated that HNF-6 binds to the promoters of two key gluconeogenic genes, G6Pase and PEPCK, and increases the transcriptional activity of both genes, and that this effect was repressed by SHP ( Figures 5B and 6) . Furthermore, when we examined the effect of PKA on HNF-6-dependent PEPCK transactivation, we found that SHP also represses the PKA-induced promoter activity of PEPCK. Previously, we showed that SHP represses G6Pase and PEPCK expression via the inhibition of HNF-3/Foxa [7] . Thus it will be critical to elucidate the regulatory pathways of both SHP and HNF-6, as there are several overlapping target genes of both factors (including PEPCK, G6Pase, CYP7A1 and HNF-3β). Moreover, since HNF-6 is involved in crucial developmental processes, including pancreatic development, endocrine differentiation, bile duct formation and the development of islet β cells [31, 32, [35] [36] [37] , it will be important to determine whether SHP has other regulatory functions involving HNF-6. Genome-scale location analysis showed that the SHP promoter is occupied by HNF-6 in human pancreatic islets [48] , which suggests that HNF-6 may be a regulator of SHP in different tissues.
SHP is an orphan NR, which means that its ligand has not yet been identified. While it is possible that there is no true ligand of SHP, structural analysis has revealed that SHP contains a hydrophobic cavity that has the potential to interact with the polar head groups of phospholipids [49] . Moreover, it has been reported that adamantyl-substituted retinoid-related molecules bind specifically to SHP and promote the interaction of SHP with a minimal co-repressor complex, comprised of Sin3A, N-CoR (nuclear receptor co-repressor), HDAC 4, and HSP90 (heat shock protein 90), resulting in transcriptional repression [50] . These results are compelling support for the continued pursuit of the identity of endogenous ligand(s) of SHP. Such ligands will be extremely useful in probing the molecular and physiological functions of SHP.
In summary, we have shown that SHP physically interacts with HNF-6 via the N-terminal region of HNF-6, and represses transcriptional activity by blocking the ability of HNF-6 to bind to target DNA sequences. Our data identifies HNF-6 as a novel target of SHP in hepatocytes. Furthermore, our findings provide evidence that SHP is a critical modulator of gluconeogenesis via the regulation of liver-enriched transcription factors, including HNF-6, HNF-3 and HNF-4. These results strengthen the case for continued pursuit of the specific ligand(s) and agonists of SHP, the identity of which will provide valuable tools for controlling glucose metabolism.
